Insider trade

10% owner sold ~$171M of LLY shares in the open market

Traded Oct 31, 2025 · Filed Nov 3, 2025

Eli LillyLLY

~$171M
Reported value · 198K sh @ $862.631: 94.3M
Holds after · shares reported: +33.3%
stock since the trade · S&P 500 +12.0%, $862.86 → $1,149.85 on Oct 1

Why it stands out

A big owner of Eli Lilly sold $171M of Eli Lilly shares. Nobody planned it ahead of time.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Oct 31, 2025
Reporting period: Not applicable
Filed with the SEC: Nov 3, 2025

10% owner$1M+

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$170,640,489

Shares × reported transaction price

Timing vs results

1 day after results of Oct 30, 2025, 96 days before results of Feb 4, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $862.86 on Oct 31, 2025, 38% above its 52-week low and 7% below its high, after a 15% rise over the previous 30 trading days

52-week range $625.65 (Aug 8, 2025) to $929.72 (Mar 3, 2025), 78% of the way up, from 250 adjusted closes. 30 trading days earlier: $751.99 on Sep 19, 2025. Describes the past only, not a forecast

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

FDA decision near the trade

FDA approved Retevmo on Nov 20, 2025, 20 days after this trade.

New use approved (efficacy supplement). Active ingredient: Selpercatinib. From openFDA. Dates only; no link between the two is implied

After it was reported

After	Stock	S&P 500	Difference
7 days	+9.0%	+1.1%	+7.9%
30 days	+11.9%	+1.4%	+10.5%
90 days	+15.1%	+3.0%	+12.2%
180 days	+6.7%	+6.3%	+0.4%

Past results only. Not a forecast.

Source receipt

Record ID: 0000316011-25-000045
Filed / recorded: Nov 3, 2025, 9:00 PM UTC
Added to OQRO: Oct 2, 2026, 3:52 AM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: ELI LILLY & Co
Issuer CIK: 59478
Ticker: LLY
Reporting person: LILLY ENDOWMENT INC
Relationship: 10% owner
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Oct 31, 2025
Transaction code: S
Shares / units: 197,814
Price per share: $862.631
Acquired / disposed: Disposed (D)
Shares owned after: 94,335,506
Ownership form: Direct
Amendment: No

Footnotes from the filing

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $862.00 to $862.98, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4), (5), (6), (7), and (8) to this Form 4.